Upgrade to SI Premium - Free Trial

Kalaris Therapeutics (KLRS)

3.90 -0.04 (1.02%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/18/26)

Latest Headlines

Kalaris Therapeutics (KLRS) Tops Q2 EPS by 2c August 11, 2026 9:34 AM - StreetInsider Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates August 11, 2026 8:00 AM - Globe NewsWire Kalaris Therapeutics names Liisa Bayko as CFO July 20, 2026 8:00 AM - StreetInsider Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer July 20, 2026 8:00 AM - Globe NewsWire Kalaris reports positive TH103 Phase 1a data in neovascular AMD July 17, 2026 7:00 AM - StreetInsider Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts July 17, 2026 7:00 AM - Globe NewsWire Kalaris Therapeutics names Laurie Keating to its board July 6, 2026 4:05 PM - StreetInsider Kalaris Appoints Laurie Keating to Board of Directors July 6, 2026 4:05 PM - Globe NewsWire Kalaris to present TH103 Phase 1a data at retina specialists meeting June 23, 2026 8:00 AM - StreetInsider Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling June 23, 2026 8:00 AM - Globe NewsWire TD Cowen Starts Kalaris (KLRS) at Buy June 15, 2026 5:32 AM - StreetInsider Kalaris to Present at Clinical Trials at the Summit 2026 June 12, 2026 8:00 AM - Globe NewsWire Full Article List